▲ +52.02% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $45.50, with a high forecast of $52.00 and a low forecast of $40.00. The average price target represents a 52.02% upside from the last price of $29.93.
The current consensus among 5 polled investment analysts is to buy stock in Pliant Therapeutics.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avÃ1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.